Literature DB >> 11665986

Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide.

G Riemekasten1, A Kawald, C Weiss, A Meine, J Marell, R Klein, B Hocher, C Meisel, G Hausdorf, R Manz, T Kamradt, G R Burmester, F Hiepe.   

Abstract

OBJECTIVE: The mechanisms of IgG anti-double-stranded DNA (anti-dsDNA) antibody induction are incompletely understood. We recently demonstrated a high prevalence of autoantibodies to the C-terminus of SmD1 in patients with systemic lupus erythematosus (SLE) that was closely associated with anti-dsDNA reactivity. The aim of the present study was to analyze the influence of the SmD1 C-terminus on the generation of pathogenic anti-dsDNA antibodies in a murine model of SLE.
METHODS: Female lupus-prone prenephritic (NZB x NZW)F1 mice (NZB/NZW mice) as well as female control BALB/c, NZW, and (BALB/c x NZW)F, mice (CWF1 mice) were subcutaneously injected with keyhole limpet hemocyanin (KLH)-coupled SmD1(83-119). Controls received injections of recombinant SmD1 (rSmD1), KLH-rSmD1, KLH-coupled randomized peptide of SmD1(83-119), ovalbumin, or saline. Animals were monitored for survival and proteinuria and for levels of plasma creatinine, urea, and autoantibodies. In addition, histologic examinations were performed and T cell responses against SmD1(83-119) peptide and rSmD1 protein were determined in SmD1(83-119)-treated and -untreated NZB/NZW mice.
RESULTS: Immunization with KLH-SmD1(83-119), but not with control peptide, significantly accelerated the natural course of lupus in NZB/NZW mice, with premature renal failure and increased development of anti-dsDNA antibodies. Control strains of mice remained healthy, with no relevant anti-SmD1(83-119) antibodies detectable even after immunization. In contrast to findings in control mice, a T cell response against SmD1(83-119) was already present in unmanipulated NZB/NZW mice, and this response was further amplified after immunization.
CONCLUSION: The SmD1(83-119) peptide can influence the pathogenic anti-dsDNA response in the NZB/NZW murine lupus model. The data suggest that an SmD1(83-119)-specific T cell response is critical. Therefore, modulation of these autoantigen-specific T cells by tolerance induction may provide a therapeutic approach to specific immunosuppression in lupus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11665986     DOI: 10.1002/1529-0131(200110)44:10<2435::aid-art408>3.0.co;2-0

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes.

Authors:  J W Dieker; C C Van Bavel; G Riemekasten; J H Berden; J van der Vlag
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

2.  Induction of pathogenic anti-dsDNA antibodies is controlled on the level of B cells in a non-lupus prone mouse strain.

Authors:  Dirk Langnickel; Philipp Enghard; Claudia Klein; Reinmar Undeutsch; Berthold Hocher; R Manz; G R Burmester; Gabriela Riemekasten
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

3.  A Central Role for HLA-DR3 in Anti-Smith Antibody Responses and Glomerulonephritis in a Transgenic Mouse Model of Spontaneous Lupus.

Authors:  Vaidehi R Chowdhary; Chao Dai; Ashenafi Y Tilahun; Julie A Hanson; Michele K Smart; Joseph P Grande; Govindarajan Rajagopalan; Shu-Man Fu; Chella S David
Journal:  J Immunol       Date:  2015-10-16       Impact factor: 5.422

Review 4.  C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity.

Authors:  Terry W Du Clos; Carolyn Mold
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens.

Authors:  Chao Jiang; Umesh S Deshmukh; Felicia Gaskin; Harini Bagavant; Julie Hanson; Chella S David; Shu Man Fu
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

6.  T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.

Authors:  G Riemekasten; C Weiss; S Schneider; A Thiel; A Bruns; F Schumann; S Bläss; G-R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

7.  Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.

Authors:  Hideo Yoshida; Minoru Satoh; Krista M Behney; Chee-Gun Lee; Hanno B Richards; Victoria M Shaheen; Jun-Qi Yang; Ram R Singh; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2002-08

8.  Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus.

Authors:  Fanny Monneaux; Véronique Parietti; Jean-Paul Briand; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

9.  Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies.

Authors:  Michael Mahler; Marvin J Fritzler; Martin Blüthner
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

Review 10.  Peptide-Based Vaccination Therapy for Rheumatic Diseases.

Authors:  Bin Wang; Shiju Chen; Qing Zheng; Yuan Liu; Guixiu Shi
Journal:  J Immunol Res       Date:  2020-03-18       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.